Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDA | P32320 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 8/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 5/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25823297 | 0.83 | CDA (0.33) | CDA | |
| SCHEMBL2851425 | 0.80 | CDA (0.41) | CDACRBNDDB1 | |
| SCHEMBL19370610 | 0.78 | OPRM1 (0.40) | CDACRBNDDB1 | |
| SCHEMBL31533494 | 0.72 | HTR2C (0.47) | — | |
| SCHEMBL25487281 | 0.70 | HTR2B (0.38) | CDACRBNDDB1 | |
| SCHEMBL23163852 | 0.70 | HTR2C (0.39) | — | |
| SCHEMBL22724570 | 0.69 | HTR2C (0.35) | — | |
| SCHEMBL25122644 | 0.69 | LMNA (0.40) | CDA | |
| SCHEMBL2674281 | 0.68 | CHRNB2 (0.42) | — | |
| SCHEMBL22144449 | 0.68 | CHRM3 (0.57) | CRBNDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025228947-A1 | BIFUNCTIONAL COMPOUNDS CAPABLE OF INDUCING DEGRADATION OF POLO-LIKE KINASE1 | CROSSFIRE ONCOLOGY B.V. (NL) | 2025-11-06 | — | — | WO | disclosed |
| EP-4634184-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING KINASES VIA UBIQUITIN PROTEOSOME PATHWAY | Crossfire Oncology Holding B.V. (NL) | 2025-10-22 | — | — | EP | disclosed |
| WO-2024126617-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING KINASES VIA UBIQUITIN PROTEOSOME PATHWAY | CROSSFIRE ONCOLOGY HOLDING B.V. (NL) | 2024-06-20 | — | — | WO | disclosed |